المؤلفون: Gomar C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Bella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Arrizabalaga L; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Gonzalez-Gomariz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Fernandez-Sendin M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Alvarez M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Russo-Cabrera JS; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Ardaiz N; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Schippers T; Hookipa Pharma Inc, New York, New York, USA., Quintero M; Highlight Therapeutics, Valencia, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Departments of Immunology and Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Orlinger KK; Hookipa Pharma Inc, New York, New York, USA., Lauterbach H; Hookipa Pharma Inc, New York, New York, USA., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain pberraondol@unav.es.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Apr 16; Vol. 12 (4). Date of Electronic Publication: 2024 Apr 16.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Lymphocytic choriomeningitis virus* , Neoplasms* , Poly I-C*, Animals ; Humans ; Mice ; Injections, Intralesional ; Tissue Distribution ; Immunotherapy/methods ; Adjuvants, Immunologic ; Tumor Microenvironment

المؤلفون: Arrizabalaga L; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. Electronic address: larrizabala@unav.es., Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Risson A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Belsúe V; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Gomar C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Ardaiz N; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Berrondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. Electronic address: faranda@unav.es., Bella Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. Electronic address: abellacarre@unav.es.

المصدر: Methods in cell biology [Methods Cell Biol] 2024; Vol. 185, pp. 67-78. Date of Electronic Publication: 2024 Mar 05.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 0373334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0091-679X (Print) Linking ISSN: 0091679X NLM ISO Abbreviation: Methods Cell Biol Subsets: MEDLINE

مواضيع طبية MeSH: Peritoneal Neoplasms*/drug therapy , Peritoneal Neoplasms*/pathology , Peritoneal Neoplasms*/secondary, Mice ; Female ; Animals ; Disease Models, Animal

المؤلفون: Bella Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Arrizabalaga L; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Gonzalez-Gomariz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Gomar C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Russo-Cabrera JS; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Olivera I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Fernandez-Sendin M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Alvarez M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Atay C; Bavarian Nordic GmbH, Martinsried, Germany., Medina-Echeverz J; Bavarian Nordic GmbH, Martinsried, Germany., Hinterberger M; Bavarian Nordic GmbH, Martinsried, Germany., Hochrein H; Bavarian Nordic GmbH, Martinsried, Germany., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Oncology and Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.; Nuffield Department of Medicine and Oxford Center for Immuno-Oncology, University of Oxford, Oxford, UK., Berraondo P; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain faranda@unav.es.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Nov; Vol. 11 (11).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Interleukin-12*/genetics , Peritoneal Neoplasms*, Animals ; Mice ; Omentum ; Vaccinia virus/genetics ; Luciferases

SCR Organism: Modified Vaccinia Ankara virus

المؤلفون: Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain., Bolaños E; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain., Luri-Rey C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain., Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain., Olivera I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain., Gomis G; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain., Glez-Vaz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain., Pinci B; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain., Garasa S; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain., Sánchez-Gregorio S; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain., Azpilikueta A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain., Eguren-Santamaria I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain., Valencia K; Program of Solid Tumors, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain., Palencia B; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain., Alvarez M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain., Ochoa MC; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain., Teijeira Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, 31008 Pamplona, Spain.; Department of Oncology, Clínica Universidad de Navarra, 28027 Madrid, Spain.; Centro Del Cancer de La Universidad de Navarra (CCUN), 31008 Pamplona, Spain.; Nuffield Department of Medicine (NDM), University of Oxford, Oxford OX3 7BN, UK.

المصدر: Molecular therapy. Nucleic acids [Mol Ther Nucleic Acids] 2023 Jul 28; Vol. 33, pp. 668-682. Date of Electronic Publication: 2023 Jul 28 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101581621 Publication Model: eCollection Cited Medium: Print ISSN: 2162-2531 (Print) Linking ISSN: 21622531 NLM ISO Abbreviation: Mol Ther Nucleic Acids Subsets: PubMed not MEDLINE

المؤلفون: Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Arrizabalaga L; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Alvarez M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain., Bella Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Fernandez-Sendin M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Russo-Cabrera JS; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Gomar C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Ardaiz N; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain., Bolaños E; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., González-Gomariz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Otano I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Palencia B; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Segués A; Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, EH9 3FL Edinburgh, UK.; Faculty of Veterinary Medicine, Department of Infectious Diseases and Immunology, Utrecht University, 3584 CS Utrecht, The Netherlands., Huang S; Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, EH9 3FL Edinburgh, UK.; Faculty of Veterinary Medicine, Department of Infectious Diseases and Immunology, Utrecht University, 3584 CS Utrecht, The Netherlands., van Duijnhoven SMJ; ImmunoPrecise Antibodies Ltd., 5349 AB Oss, The Netherlands., van Elsas A; Third Rock Ventures, San Francisco, CA 94158, USA., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.

المصدر: Molecular therapy. Nucleic acids [Mol Ther Nucleic Acids] 2023 Jul 19; Vol. 33, pp. 599-616. Date of Electronic Publication: 2023 Jul 19 (Print Publication: 2023).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101581621 Publication Model: eCollection Cited Medium: Print ISSN: 2162-2531 (Print) Linking ISSN: 21622531 NLM ISO Abbreviation: Mol Ther Nucleic Acids Subsets: PubMed not MEDLINE

المؤلفون: Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Bolaños E; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., de Andrea CE; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Department of Pathology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.; Department of Anatomy, Physiology and Pathology, University of Navarra, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Sánchez-Gregorio S; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Etxeberria I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Gonzalez-Gomariz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Olivera I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Brocco D; Department of Pharmacy, University 'G. D'Annunzio' Chieti-Pescara, Chieti, Italy., Glez-Vaz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Luri-Rey C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Azpilikueta A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Rodríguez I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Fernandez-Sendín M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Egea J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Eguren I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Sanmamed MF; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Oncology, Clinica Universidad de Navarra, Madrid, Spain., Palencia B; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Oncology, Clinica Universidad de Navarra, Madrid, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.

المصدر: Cancer immunology research [Cancer Immunol Res] 2023 Feb 03; Vol. 11 (2), pp. 184-198.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE

مواضيع طبية MeSH: Interleukin-18* , Neoplasms*/genetics , Neoplasms*/therapy, Animals ; Mice ; CD8-Positive T-Lymphocytes ; Immunotherapy ; Interleukin-12/metabolism

المؤلفون: Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Arrizabalaga L; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Bella Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Fernandez-Sendin M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Russo-Cabrera JS; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Gomar C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Olivera I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Bolaños E; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., González-Gomariz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Álvarez M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain., Etxeberria I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Palencia B; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Teijeira Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.; Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain., Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona, Spain.

المصدر: Oncoimmunology [Oncoimmunology] 2022 Dec 15; Vol. 12 (1), pp. 2147317. Date of Electronic Publication: 2022 Dec 15 (Print Publication: 2023).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE

مواضيع طبية MeSH: CD8-Positive T-Lymphocytes* , Peritoneal Neoplasms*/therapy, Mice ; Animals ; Interleukin-12/genetics ; RNA, Messenger/genetics ; Adoptive Transfer ; Antigens, Neoplasm/genetics ; Disease Models, Animal ; Tumor Microenvironment

المؤلفون: Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Luri-Rey C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Department of oncology, Clinica Universidad de Navarra, Madrid, Spain., Olivera I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Bolaños E; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Castañón E; Department of oncology, Clinica Universidad de Navarra, Madrid, Spain., Palencia B; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain., Brocco D; Department of Pharmacy, University 'G. D'Annunzio' Chieti-Pescara, Chieti, Italy., Fernández-Sendin M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain; Department of oncology, Clinica Universidad de Navarra, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain; Department of Immunology and immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain. Electronic address: imelero@unav.es.

المصدر: Pharmacology & therapeutics [Pharmacol Ther] 2022 Nov; Vol. 239, pp. 108189. Date of Electronic Publication: 2022 Apr 14.

نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 7905840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-016X (Electronic) Linking ISSN: 01637258 NLM ISO Abbreviation: Pharmacol Ther Subsets: MEDLINE

مواضيع طبية MeSH: Interleukin-12*/genetics , Neoplasms*/therapy, Humans ; Immunotherapy/methods ; Genetic Vectors ; Immunotherapy, Adoptive ; Immunologic Factors

المؤلفون: Bella Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Arrizabalaga L; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Cirella A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Fernandez-Sendin M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Gomar C; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Russo-Cabrera JS; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Rodríguez I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., González-Gomariz J; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Alvarez M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Teijeira Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Medina-Echeverz J; Immunology Research, Bavarian Nordic GmbH, Planegg, Germany., Hinterberger M; Immunology Research, Bavarian Nordic GmbH, Planegg, Germany., Hochrein H; Immunology Research, Bavarian Nordic GmbH, Planegg, Germany., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

المصدر: Oncoimmunology [Oncoimmunology] 2022 Jul 13; Vol. 11 (1), pp. 2098657. Date of Electronic Publication: 2022 Jul 13 (Print Publication: 2022).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE

مواضيع طبية MeSH: Peritoneal Neoplasms*/therapy , Vaccinia*, 4-1BB Ligand/*metabolism, Animals ; CD40 Ligand/genetics ; Immunity ; Mice ; Vaccinia virus/genetics

المؤلفون: Bella Á; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. Electronic address: abellacarre@unav.es., Arrizabalaga L; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Di Trani CA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Fernández-Sendin M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Teijeira A; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Russo-Cabrera JS; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain., Melero I; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Translational Oncology Group, Program in Solid Tumors, Cima Universidad de Navarra, Pamplona, Spain; Department of Immunology and Immunotherapy, Clinica Universidad de Navarra, Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Aranda F; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. Electronic address: faranda@unav.es.

المصدر: International review of cell and molecular biology [Int Rev Cell Mol Biol] 2022; Vol. 371, pp. 117-131. Date of Electronic Publication: 2022 Jun 27.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101475846 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1937-6448 (Print) Linking ISSN: 19376448 NLM ISO Abbreviation: Int Rev Cell Mol Biol Subsets: MEDLINE

مواضيع طبية MeSH: Ovarian Neoplasms*/pathology , Ovarian Neoplasms*/surgery , Peritoneal Neoplasms*/pathology , Peritoneal Neoplasms*/therapy, Female ; Humans ; Immunologic Factors ; Immunotherapy ; Omentum/pathology ; Omentum/surgery